Diametric Capital’s Definium Therapeutics DFTX Stock Holding History

Diametric Capital’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-12,433	Closed	-$80.7K	–	447
2025 Q2	$80.7K	Sell	12,433 -937	-7%	-$6.16K	0.04%	300
2025 Q1	$78.2K	Sell	13,370 -2,080	-13%	-$14.9K	0.09%	181
2024 Q4	$108K	Buy	+15,450	New	+$106K	0.07%	272

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Diametric Capital's DFTX Position: Q3 2025 in Review

Diametric Capital sold out of Definium Therapeutics (DFTX) in Q3 2025, closing a stake of 12,433 shares — an estimated $80.7K sold.

Diametric Capital first reported a position in DFTX in Q4 2024 and held it in 3 quarters. The position peaked at $108K in Q4 2024. 195 funds tracked by Wall St. Rank hold DFTX as of Q3 2025.

Diametric Capital reported no remaining Definium Therapeutics position as of Q3 2025 after selling out during the quarter.
Diametric Capital sold 12,433 Definium Therapeutics shares in Q3 2025, an estimated $80.7K.
Diametric Capital first reported a position in Definium Therapeutics in Q4 2024 and held it in 3 quarters.
Diametric Capital's Definium Therapeutics position peaked at $108K in Q4 2024.
195 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2025.

Based on Diametric Capital's 13F filing for Q3 2025, filed 13 Nov 2025.